Sun, Dec 28, 2014, 6:21 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

KIT digital, Inc. Message Board

robmengnny 163 posts  |  Last Activity: Dec 26, 2014 3:23 PM Member since: Jun 28, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Brean Capital Reiterates Buy On Repros Following Positive Top-Line Results
    September 26, 2014 12:53 PM EDT by Editor Corey Williams in Exclusively Published, Healthcare
    In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a price target of $41.00.

    Aschoff commented: “Repros released positive top-line results from the second of its two identical Phase 3 trials comparing Androxal head to head with AndroGel and placebo. As it did in its first Phase 3 trial, ZA-305, Androxal achieved superiority over AndroGel in both co-primary endpoints in ZA-304. Moreover, the efficacy deltas between Androxal and AndroGel were favorably larger in ZA-304 than in ZA-305. We look forward to the long-term safety data in mid-October and a pre-NDA meeting with the FDA by, in our view, the end of November, which should provide more clarity on the FDA’s thoughts about Androxal post the September 17 advisory panel and on secondary hypogonadism in general. Repros will host an Analyst Day on October 31. Four SAEs occurred, two in the Androxal arm, one in the AndroGel arm, and one in the placebo arm, although none of them were deemed drug-related. One patient on Androxal 12.5mg who at entry already had multiple risk factors for stroke (untreated atrial fibrillation, diabetes, obesity and hyperlipidemia), had a fatal ischemic stroke; another patient on Androxal 12.5mg who had a history of alcohol abuse and a recent hospital admission due to an anxiety attack was killed in a motor vehicle accident. A patient on AndroGel with known cardiac disease and stents was found to have coronary artery occlusion on routine follow-up, and was subsequently hospitalized for bypass surgery. A patient on placebo was hospitalized because of intractable vomiting due to gastroenteritis.”

    Sentiment: Strong Buy

  • Reply to

    $4 CLOSE LONGS WHY?

    by supremacy_shorting_trolls Oct 1, 2014 10:27 AM
    robmengnny robmengnny Oct 1, 2014 10:38 PM Flag

    Unfortunately, you were not right, Sir.

    Sentiment: Strong Buy

  • robmengnny robmengnny Oct 1, 2014 10:37 PM Flag

    See today, how many long "buy him"?

    Sentiment: Strong Buy

  • robmengnny robmengnny Oct 1, 2014 10:34 PM Flag

    Mati just win a patent case

    Sentiment: Strong Buy

  • robmengnny by robmengnny Oct 1, 2014 10:10 PM Flag

    We shall see a bigger jump in the next few days.
    1. Last two day trading volume is about 31.5 m(20m+11.5m)., which is about 30% of the float(106m). This is a top figure for investors who have a strong wish to sell the stock. We expecting the rest of 70% would wish to hold down.
    2. Short total 800k (420+380k), less than 2%. This figure is less than 5% of last month avg.
    3. Amount 31.5 shares, I believe more than 4m short have covered their shares.
    4. Since stock was cut in half, more existing longs would like to buy more shares to leverage down their prices.
    5. Check the whole market, this is the cheapest stock with no fundamental wrong.
    6. As the price going up, there will be no short sellers to against the trend.

    So before reaching to $16, there will be not too many sellers. In another word, stock will be recovered back to $16 in a short period of time.

    Sentiment: Strong Buy

  • Today stock is down. Russell 2000 get to the lowest point. Now it is a market where funds looking for cheap rather than follow the wave to buy at the dip. CVEO is a perfect stock for funds to play.
    1. No fundamental wrong with the company.
    Going to "C Corp" vs "REIT" insure the company has the right amount of cash flow.
    2. Relocating to Canada will save 4-5% tax expenses
    Thus, although the company projected a slow in coming quarter, we shall see this tax savings will actually help to improve Financial Statements.
    3. Keeping Current Dividend payment will not be a problem
    4. Stock has been cut in half
    5. Expecting earning double in the future quarters
    13cents tax saving will added up to 30cents earning in the current saving, which is about 30% improvement.
    6. CEO and a insider bought yesterday
    They showed their confidence for the future Qs.

    That's why we saw today, CVEO is outstanding in the bear market.

    Sentiment: Strong Buy

  • robmengnny by robmengnny Oct 1, 2014 11:43 AM Flag

    For sure

    Sentiment: Strong Buy

  • Reply to

    About the short volume

    by robmengnny Sep 30, 2014 9:41 PM
    robmengnny robmengnny Oct 1, 2014 12:43 AM Flag

    I don't think so that the short volume only from Scottrade. What is about the volume? 20m from Scottrade, too? I don't think so. There are many parameters you can choose from. It supposed to be all for the entire market.

    Sentiment: Strong Buy

  • We can see:
    1. No insiders buy
    2. Keep selling with higher price
    3. Price jumped up more than they expected
    4.They feel a top
    5. There are no M&A
    6. Because you believed the Analyst Rating for $140, but they don't believe
    7. The price will crush soon
    8. Ask yourself why you buy?
    9 They may do a little pump news later, because the treasury have been stolen, they give you a Alert to walk away.

    Never see a Board like that. Idiot investors! Pity investors!
    .

    Sentiment: Strong Sell

  • robmengnny by robmengnny Sep 30, 2014 11:41 PM Flag

    Why you buy and hold?

    Sentiment: Strong Sell

  • robmengnny by robmengnny Sep 30, 2014 11:41 PM Flag

    9/25/2014 Martine A Rothblatt CEO Sell 5,547 $134.26 $744,740.22 View Tweet This Trade Share This Trade on StockTwits
    9/25/2014 Paul A Mahon EVP Sell 5,000 $133.77 $668,850.00 View Tweet This Trade Share This Trade on StockTwits
    9/25/2014 Richard Giltner Director Sell 20,000 $134.94 $2,698,800.00 View Tweet This Trade Share This Trade on StockTwits
    9/23/2014 Roger Jeffs COO Sell 50,000 $131.02 $6,551,000.00 View Tweet This Trade Share This Trade on StockTwits
    9/19/2014 Roger Jeffs COO Sell 10,000 $129.60 $1,296,000.00 View Tweet This Trade Share This Trade on StockTwits
    9/18/2014 John Maxim Ferrari CFO Sell 10,000 $130.93 $1,309,300.00 View Tweet This Trade Share This Trade on StockTwits
    9/18/2014 Martine A Rothblatt CEO Sell 9,662 $127.35 $1,230,455.70 View Tweet This Trade Share This Trade on StockTwits
    9/18/2014 Paul A Mahon EVP Sell 6,000 $130.93 $785,580.00 View Tweet This Trade Share This Trade on StockTwits
    9/17/2014 Roger Jeffs COO Sell 20,000 $127.01 $2,540,200.00 View Tweet This Trade Share This Trade on StockTwits
    9/15/2014 Martine A Rothblatt CEO Sell 50,000 $124.52 $6,226,000.00 View Tweet This Trade Share This Trade on StockTwits
    9/11/2014 Martine A Rothblatt CEO Sell 9,662 $120.79 $1,167,072.98 View Tweet This Trade Share This Trade on StockTwits
    9/11/2014 Paul A Mahon EVP Sell 5,000 $120.70 $603,500.00 View Tweet This Trade Share This Trade on StockTwits
    9/10/2014 Martine A Rothblatt CEO Sell 50,000 $120.01 $6,000,500.00 View Tweet This Trade Share This Trade on StockTwits
    9/10/2014 Richard Giltner Director Sell 20,000 $119.95 $2,399,000.00 View Tweet This Trade Share This Trade on StockTwits
    9/5/2014 Roger Jeffs COO Sell 10,000 $111.29 $1,112,900.00 View Tweet This Trade Share This Trade on StockTwits
    9/4/2014

    Sentiment: Sell

  • robmengnny by robmengnny Sep 30, 2014 11:18 PM Flag

    Can Repros Therapeutics Shares Still More Than Double?
    By Jon C. Ogg September 29, 2014 1:10 pm EDT

    Print Email
    inShare


    Repros Therapeutics Inc. (NASDAQ: RPRX) is a small cap biotech stock that is not exactly having the best year, despite big gains on Friday. With shares close to $10, its 52-week range of $8.46 to $28.99 signals just how hard of a year it has been. So, what do you do when an analyst report comes out that maintains a price target position that implies shares can more than a double ahead?

    A Bank of America Merrill Lynch report on Monday maintained a Buy rating and kept a $24 price target objective on the stock. The call is from Steve Byrne, Tazeen Ahmad and Sara Blum, talking up positive Androxal data and noting significant long-term potential for the stock.

    Repros was shown in the report as having its second Androxal study positive, and a pre-new drug application (NDA) meeting has been scheduled with the FDA. The analysts indicated that Repros reported positive top-line data from its 304 study of Androxal vs. AndroGel, following prior favorable results from the first of two pivotal trials. They also noted that Repros has scheduled its Type B pre-NDA meeting in the first half of November and reiterated expectations to file a new drug application near year-end 2014.

    Read more: Can Repros Therapeutics Shares Still More Than Double? (NASDAQ: RPRX) - 24/7 Wall St. http://247wallst.com/healthcare-business/2014/09/29/can-repros-therapeutics-shares-still-more-than-double/#ixzz3ErN3gNRI
    Follow us: @247wallst on Twitter | 247wallst on Facebook

    Read more: Can Repros Therapeutics Shares Still More Than Double? (NASDAQ: RPRX) - 24/7 Wall St. http://247wallst.com/healthcare-business/2014/09/29/can-repros-therapeutics-shares-still-more-than-double/#ixzz3ErMjZfb3
    Follow us: @247wallst on Twitter | 247wallst on Facebook

    Sentiment: Strong Buy

  • robmengnny by robmengnny Sep 30, 2014 10:32 PM Flag

    EVA Dimensions upgrades CVEO from HOLD to Overweight

    Sentiment: Strong Buy

  • Reply to

    Insider Buys

    by robmengnny Sep 30, 2014 10:20 PM
    robmengnny robmengnny Sep 30, 2014 10:30 PM Flag

    Insider spend $300k and buy, how much you want to take the loss?

    Sentiment: Strong Buy

  • REIT Qualifications

    Civeo said a REIT conversion would cost $720 million. To qualify as a REIT, a company must invest at least 75 percent of its assets in real estate and obtain 75 percent of its gross income from rents or interest on mortgages from financing property, according to the National Association of Real Estate Investment Trusts, a Washington-based trade group.

    U.S. tax laws allow a company to move its address out of the country without penalty if the company has substantial business activities in the other area. In its statement, Civeo described the move as a “self-directed redomiciling.” The company also said the Treasury Department’s recent proposed limits on corporate address changes known as inversions aren’t expected to affect Civeo’s move.

    Civeo estimated revenue of $200 million to $210 million for the fourth quarter, and $900 million to $920 million for the full year.

    I don't think this company will continue falling! Buy more tomorrow.

    Sentiment: Strong Buy

  • robmengnny by robmengnny Sep 30, 2014 10:20 PM Flag

    9/30/2014 Bradley J Dodson Insider Buy 24,000 $12.86 $308,640.00
    9/30/2014 Gary L Rosenthal Director Buy 8,000 $12.21 $97,680.00

    Sentiment: Strong Buy

  • robmengnny by robmengnny Sep 30, 2014 10:15 PM Flag

    1. The next Div will be kept at 13cent.. Since company will relocate in Canada in 5-8months. But maybe the accounting method can be changed overnight.

    2. If they can save 4-5% on tax later, that is about 52 cent, so the Div is not a burden

    3. Even they projected a slow down business, this 4-5% save can help the company make the financial statement NICER, or it can give Wall Street a surprise in the coming Qs

    4. Earnings projected to be 22cents and 14 cents respectively, but with 4-5% tax savings, which is equal to 52cents. We shall see a big improvement in the Q2/05. So for long term investors, today's price is so cheap!

    5. We won't expect too much price voilatile during the Q3 and Q4, as everything is projected, and the price is already reflecting for such a change.

    6. "C Corp" vs. "Reit" is not make too much different for the company, as so far 13cents Div is not a big deal to the company later.

    7. As the winter comes, energy requirement will be added up, So if the business getting better, not as they said in Q2 10-Q, we shall see price back to $20.shortly.

    Sentiment: Strong Buy

  • Reply to

    About the short volume

    by robmengnny Sep 30, 2014 9:41 PM
    robmengnny robmengnny Sep 30, 2014 9:44 PM Flag

    Don't blame the short, blame the long who sold it.

  • Reply to

    6 reasons to hold

    by robmengnny Sep 30, 2014 4:25 PM
    robmengnny robmengnny Sep 30, 2014 9:42 PM Flag

    Please check my post

  • robmengnny by robmengnny Sep 30, 2014 9:41 PM Flag

    I use Scottrade Elite, There, you can find yesterday's short is 424785 shares. Longs, please don't be scared by yesterday 20m trade volume. Shorts did not scare you,but longs. I will say short volume is very low now. Imagine, yesterday, shorts made more than $10. I assumed almost every shorts covered their shares. You see $10 huge money put on your table, do you still care to make another 20centts?

    So, among 20m volume, it is reasonable to think that nearly every shorts want to cover (shorts was about 5%, roughly 4.4m). As I said, longs, please no panic please. Shorts are drying out. If you don't sell it, the market soon will be turned around.

    Sentiment: Strong Buy

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TherapeuticsMD, Inc.
AMEXFri, Dec 26, 2014 4:01 PM EST
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST